<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <link rel="stylesheet" href="./css/bootstrap.min.css">
    <link rel="stylesheet" href="./css/all.min.css">
    <link rel="stylesheet" href="./css/fontawesome.min.css">
    <link rel="stylesheet" href="./css/style.css">
    <title>Diabetes 360 eMagazine</title>
</head>
<body>


    <div class="container">
    <div class="main">
        <div class="left">
            <a href="./page-12.html"><img src="./img/prev.png" alt="previous"></a>
        </div>
        <div class="right">
            <a href="./page-14.html"><img src="./img/next.png" alt="next"></a>
        </div>
        
        <header class="pages-header-footer pages-h-f-white">
            <div class="row align-items-center m-0">
                <div class="col-3 header-txt header-txt-black"><p class=" m-0">NEWSLETTER in Diabetes</p></div>
                <div class="col-7 align-content-center"><div class="dark-line"></div></div>
                <div class="col-2"><img src="img/sanofi-logo-black.png" alt=""></div>
            </div>
        </header>
        <div class="article-head">
            <h1 class="headline"><span class="bold">Teplizumab: Type 1 Diabetes Mellitus Preventable?</span>
            </h1>
                <hr>
            <div class="subheader">
                <p class="primary-col">Source: Misra S, Shukla AK. Teplizumab: type 1 diabetes mellitus preventable? Eur J Clin Pharmacol. 2023 May;79(5):609- 616. doi:
                    10.1007/s00228-023-03474-8.</p>
            </div>
        </div>
        <article>
            <div class="col-12">
                <div class="feature-img">
                    <img src="./img/magazine-edit-13-3-16.jpg" alt="feature-img">
                </div>
            </div>
            <div class="row">
                <div class="col-lg-6 col-sm-12">
                    
                    <p>
                        Type 1 diabetes mellitus (T1DM) is an autoimmune
                        condition driven by T lymphocytes that specifically
                        declines the function of beta cells of pancreas.
                        Immunological treatments aim to stop this decline in
                        ß-cell function thus preventing TIDM. Although TIDM
                        occur at any age, it is one of the most common chronic
                        disorders in children. T1DM accounts for 5 to 10% of all
                        cases of diabetes amounting 21-42 million affected
                        persons. Teplizumab is a novel drug recently approved
                        by the US FDA for the treatment of T1DM.
                    </p>

                    <p>This drug reduces abnormal glucose tolerance who are
                        at high risk for developing T1DM and have antibodies
                        suggesting an immunological attack on their pancreas.
                        A 14-day infusion of the drug prevents T cells’ attack
                        of the insulin-producing cells of the pancreas. Adverse
                        events due to teplizumab reported so far mild and of
                        limited duration.
                    </p>
                    <p>This review gave an overview of the preclinical and clinical
                        research on teplizumab for their role in new-on-set T1DM.
                    </p>
                    <p>T1DM, type 1 diabetes mellitus; FDA, Food and Drug Administration</p>
    
                </div>
    
                <div class="col-lg-6 col-sm-12">
                    <div class="purple-quote primary-bg">
                        <div class="quotes"><img src="./img/quotes.png" alt=""></div>
                        <h3>Conclusion</h3>
                        <p>
                            A 14-day infusion of teplizumab, an anti-CD3
                            immunotherapy, prevents T cells’ attack of the
                            insulin-producing cells of the pancreas.<br>
                            Drug has been found to be effective in
preclinical and clinical studies. It was shown
to improve the metabolic responses and delay
the onset of diabetes Adverse events due to
teplizumab reported so far mild and of limited
duration. Evidence from metanalyses and
other randomized controlled trials (RCT) show
that teplizumab treatment preserves insulin
production and reduces the use of exogenous
insulin in some patients with new-onset T1DM.
                        </p>
                    </div>
                    
                </div>
            </div>
            
            <div class="article-footer">
                <div class="row">
                    <div class="col-lg-6 col-sm-12">
                        <div class="ref-rating">
                            <p>
                                T1DM, type 1 diabetes mellitus; FDA, Food and Drug Administration
                            </p>                    
                        </div>
                        <div class="rating">
                            <p>How do you rate this article?</p>
                            <div class="row px-4">
                                <div class="col p-1"><a href="https://dta.eu.qualtrics.com/jfe/form/SV_efWbOu2lUz2aZpQ?CO=EG&Q_Language=EN&Brand=Unbranded&CN=Diabetes_360_eMagazine&Channel=E-NewsLetter&Function=Medical&Franchise=Diabetes_Core&TA=Diabetes&DA=Type_1_Diabetes&R=1" target="_blank"><img src="./img/red-1.png" alt="rate1"></a></div>
                                <div class="col p-1"><a href="https://dta.eu.qualtrics.com/jfe/form/SV_efWbOu2lUz2aZpQ?CO=EG&Q_Language=EN&Brand=Unbranded&CN=Diabetes_360_eMagazine&Channel=E-NewsLetter&Function=Medical&Franchise=Diabetes_Core&TA=Diabetes&DA=Type_1_Diabetes&R=2" target="_blank"><img src="./img/orange-2.png" alt="rate2"></a></div>
                                <div class="col p-1"><a href="https://dta.eu.qualtrics.com/jfe/form/SV_efWbOu2lUz2aZpQ?CO=EG&Q_Language=EN&Brand=Unbranded&CN=Diabetes_360_eMagazine&Channel=E-NewsLetter&Function=Medical&Franchise=Diabetes_Core&TA=Diabetes&DA=Type_1_Diabetes&R=3" target="_blank"><img src="./img/mustard-3.png" alt="rate3"></a></div>
                                <div class="col p-1"><a href="https://dta.eu.qualtrics.com/jfe/form/SV_efWbOu2lUz2aZpQ?CO=EG&Q_Language=EN&Brand=Unbranded&CN=Diabetes_360_eMagazine&Channel=E-NewsLetter&Function=Medical&Franchise=Diabetes_Core&TA=Diabetes&DA=Type_1_Diabetes&R=4" target="_blank"><img src="./img/yellow-4.png" alt="rate4"></a></div>
                                <div class="col p-1"><a href="https://dta.eu.qualtrics.com/jfe/form/SV_efWbOu2lUz2aZpQ?CO=EG&Q_Language=EN&Brand=Unbranded&CN=Diabetes_360_eMagazine&Channel=E-NewsLetter&Function=Medical&Franchise=Diabetes_Core&TA=Diabetes&DA=Type_1_Diabetes&R=5" target="_blank"><img src="./img/green-5.png" alt="rate5"></a></div>
                                <div class="col p-1"><a href="https://dta.eu.qualtrics.com/jfe/form/SV_efWbOu2lUz2aZpQ?CO=EG&Q_Language=EN&Brand=Unbranded&CN=Diabetes_360_eMagazine&Channel=E-NewsLetter&Function=Medical&Franchise=Diabetes_Core&TA=Diabetes&DA=Type_1_Diabetes&R=6" target="_blank"><img src="./img/turquoise-6.png" alt="rate6"></a></div>
                                <div class="col p-1"><a href="https://dta.eu.qualtrics.com/jfe/form/SV_efWbOu2lUz2aZpQ?CO=EG&Q_Language=EN&Brand=Unbranded&CN=Diabetes_360_eMagazine&Channel=E-NewsLetter&Function=Medical&Franchise=Diabetes_Core&TA=Diabetes&DA=Type_1_Diabetes&R=3" target="_blank"><img src="./img/aquamarine-7.png" alt="rate7"></a></div>
                            </div>
                            <div class="rating-bar">
                                <img src="./img/rating-1-5.png" alt="">
                            </div>  
                        </div>
                    </div>
                </div>
            </div>
        </article>
        </div>
        <footer class="footer">
            <div class="pages-header-footer">
                <div class="row">
                    <div class="col-1">
                        <div class="pagination">
                            <p>5</p>
                        </div>
                    </div>
                    <div class="col-8 align-content-center p-0">
                        <div class="dark-line"></div>
                    </div>
                    <div class="col-3 d-flex justify-content-center align-items-center">
                        <div class="header-txt-black header-txt">The 360 e-Magazine</div>
                    </div>
                </div>
            </div>
        
    </footer>

        </div>

    </div>    
    </div>


    <script src="./js/bootstrap.bundle.min.js"></script>
    </body>
</html>